comprehensive -WSS

comprehensive

author：comprehensive 2025-09-03 09:24:59 - browse：8

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Are infertility treatments 'essential' during the Covid

leisure time

WSS

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Illinois to ban advertising for guns allegedly marketed to kids and militants

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

The UK government moves asylum

US jobless claims fall again as labor market continues to flash strength

leisure time

comprehensive

focus

Cancer drug shortages should be causing more outrage

Mississippi candidates for statewide offices square off in party primaries

Virginia high school admissions case could be legal follow

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Psychedelics group wrestles with new pharma identity

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Moonlake's readout produced a cash windfall. Risks remain

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

George Santos makes 1st court appearance after pleading not guilty to 13 counts

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

knowledge

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

After a decade, new Gardasil ad campaign gets it (mostly) right

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Why workplace violence is so common in health care

Mystery swirls around US soldier who entered North Korea days ago, officials say

hotspot

leisure time

hotspot

hotspot